Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745324 | 1.00 | CYP2C9 (0.49) | CYP2C9CYP1A2CYP2C19MIFALDH1A1 | |
| SCHEMBL2744965 | 0.86 | CYP2C9 (0.56) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL20040052 | 0.84 | PSEN1 (0.34) | CYP2C9CYP1A2CYP2C19ALDH1A1CASP1 | |
| SCHEMBL2745254 | 0.82 | CYP1A2 (0.59) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL2745414 | 0.80 | CYP2C9 (0.51) | CYP2C9CYP1A2CYP2C19MIFALDH1A1 | |
| SCHEMBL2745478 | 0.77 | CYP2C9 (0.48) | CYP2C9CYP1A2CYP2C19MIFALDH1A1 | |
| SCHEMBL2745455 | 0.77 | CYP1A2 (0.48) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL2745134 | 0.77 | SLC6A2 (0.35) | — | |
| SCHEMBL2745297 | 0.76 | SLC6A2 (0.49) | CYP3A4 | |
| SCHEMBL2689170 | 0.75 | SLC6A2 (0.60) | CYP2C9CYP1A2CYP2C19MIFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3091012-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CENTREXION THERAPEUTICS CORP (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2813503-B1 | A process for the production of new CCR2 receptor antagonists and intermediates thereof | CT XION THERAPEUTICS CORP (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2813503-A1 | A process for the production of new CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2513093-B1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-20140235661-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-21 | — | — | US | disclosed |
| US-20140235661-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-21 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP1A2 755/4885CYP2C19 1913/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP1A2 755/4885CYP2C19 1913/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 2290/4885CYP1A2 1045/4885CYP2C19 2239/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP1A2 755/4885CYP2C19 1913/4885 |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP1A2 755/4885CYP2C19 1913/4885 |
| US-20140235661-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 2290/4885CYP1A2 1045/4885CYP2C19 2239/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 2290/4885CYP1A2 1045/4885CYP2C19 2239/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP1A2 755/4885CYP2C19 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.